I now have comprehensive content from Harrison's 22E covering all aspects of meningitis. Let me now compile the full seminar notes.Here is the comprehensive seminar notes on Meningitis in the context of Pyrexia of Unknown Origin (PUO), compiled from Harrison's Principles of Internal Medicine 22E (2025), Goldman-Cecil Medicine, Adams and Victor's Principles of Neurology 12E, and Bradley and Daroff's Neurology in Clinical Practice.
MENINGITIS
A Comprehensive Seminar Reference — In the Context of Pyrexia of Unknown Origin (PUO)
MENINGITIS AND PUO — THE CLINICAL LINK
PUO is classically defined as fever >38.3°C on multiple occasions over >3 weeks, with no diagnosis established after 3 outpatient visits or 3 days of inpatient investigation. Meningitis — particularly subacute and chronic forms (tuberculous, cryptococcal, aseptic, carcinomatous, and partially-treated bacterial) — is a recognised cause of PUO. Patients with these forms may present with persistent fever, headache, and subtle or absent meningism, making the diagnosis easily missed. Any patient presenting with PUO and headache, neck stiffness, altered cognition, or cranial nerve palsies should undergo CSF examination.
"Persistent fever with headache demands CSF examination." — Harrison's Principles of Internal Medicine 22E
1. DEFINITION
Bacterial meningitis is an acute purulent infection within the subarachnoid space (SAS). It is associated with a CNS inflammatory reaction that may result in decreased consciousness, seizures, raised intracranial pressure (ICP), and stroke. The meninges, SAS, and brain parenchyma are all frequently involved in the inflammatory reaction (meningoencephalitis).
— Harrison's 22E, Chapter 143
By the Goldman-Cecil definition: Meningitis is an inflammation of the arachnoid membrane, the pia mater, and the intervening CSF. The inflammatory process extends throughout the subarachnoid space around the brain and spinal cord and involves the ventricles. Pyogenic meningitis is usually an acute bacterial infection evoking a polymorphonuclear (PMN) response in CSF, while tuberculous meningitis is often subacute and characterised initially by a modest PMN pleocytosis that rapidly evolves to lymphocytic predominance.
— Goldman-Cecil Medicine, Chapter 381
Types of Meningitis by Aetiology:
| Type | Typical Course | Key Organisms/Causes |
|---|
| Bacterial (pyogenic) | Acute (hours–days) | S. pneumoniae, N. meningitidis, L. monocytogenes |
| Viral (aseptic) | Acute, self-limiting | Enteroviruses, HSV-2, VZV, HIV, EBV |
| Tuberculous | Subacute–chronic (weeks) | Mycobacterium tuberculosis |
| Fungal | Subacute–chronic | Cryptococcus neoformans |
| Non-infectious | Variable | Sarcoidosis, malignancy, drugs, SLE |
2. EPIDEMIOLOGY
Bacterial Meningitis
- Annual incidence in developed countries: ~1.4 cases/100,000 population (United States), and 0.5–1.5/100,000 in other developed nations — Harrison's 22E; Goldman-Cecil
- The incidence has dropped dramatically following vaccine introduction (Hib conjugate, pneumococcal, meningococcal vaccines)
- Since introduction of the Hib vaccine, S. pneumoniae has become the most common pathogen, accounting for ~70% of adult cases — Goldman-Cecil
- The disease is now more common in older adults than in children — Goldman-Cecil
- Mortality rate remains ~15–20% despite antibiotic therapy — Goldman-Cecil; Harrison's
- Worldwide, incidence is related to poverty and remains a major cause of mortality and morbidity
- Nosocomial meningitis accounts for an increasing proportion of cases in tertiary hospitals (~40% in some series)
- N. meningitidis causes recurring epidemics every 8–12 years — Harrison's 22E
Age Distribution of Causative Organisms:
| Age Group | Predominant Organism |
|---|
| Neonates (<1 month) | Group B Streptococcus, E. coli, L. monocytogenes |
| Children (1 month–5 years) | S. pneumoniae, N. meningitidis, H. influenzae |
| Adolescents/Young adults | N. meningitidis, S. pneumoniae |
| Adults >20 years | S. pneumoniae (~50%), N. meningitidis (~25%) |
| Elderly/Immunocompromised | S. pneumoniae, L. monocytogenes, Gram-negative bacilli |
Viral Meningitis
- Enteroviruses are the dominant cause worldwide, responsible for ~50% of all cases of meningitis and encephalitis in the United States — Goldman-Cecil
- Viral meningitis is far more common than bacterial meningitis but carries a much better prognosis
Fungal/Cryptococcal Meningitis
- Cryptococcal meningitis is predominantly seen in HIV/AIDS patients with CD4 count <100 cells/μL
- In the early 1990s, there were >1,000 cases/year in New York City alone — a figure exceeding all cases of bacterial meningitis — Harrison's 22E
- Mortality: 10–25% in developed countries, up to 43% in resource-poor settings — Bradley and Daroff's
Malaysia/Southeast Asia Context
- TB meningitis is particularly relevant in Malaysia given the high burden of tuberculosis in Southeast Asia
- Angiostrongylus cantonensis (rat lungworm) is the most common global cause of eosinophilic meningitis, with high endemicity in Southeast Asia and the Pacific — Adams and Victor's 12E
- Gnathostoma spinigerum causes severe eosinophilic meningoencephalitis in Southeast Asia, including Malaysia — Adams and Victor's
- Melioidosis (Burkholderia pseudomallei) is an important endemic cause of meningitis in Southeast Asia — Adams and Victor's
3. AETIOLOGY
Bacterial Causes
| Organism | Key Risk Factors / Notes |
|---|
| S. pneumoniae | Most common in adults; risk factors: pneumonia, sinusitis, otitis media, alcoholism, DM, asplenia, hypogammaglobulinaemia, complement deficiency, basilar skull fracture with CSF rhinorrhoea. Mortality ~20% |
| N. meningitidis | Young adults, adolescents; petechial/purpuric rash; complement deficiency increases risk; endemic/epidemic potential |
| L. monocytogenes | Neonates, elderly >60 years, pregnant women, immunocompromised, patients on corticosteroids; from contaminated food (coleslaw, soft cheese, deli meats). Mortality ~15% |
| Group B Streptococcus (S. agalactiae) | Neonates and adults >50 years with underlying disease. Mortality 3–7% |
| H. influenzae type b | Dramatically declined since Hib vaccine; now unvaccinated children and older adults |
| Gram-negative bacilli (E. coli, Klebsiella, Pseudomonas) | Diabetes, cirrhosis, alcoholism, UTI, neurosurgical procedures, CSF rhinorrhoea/otorrhoea |
| S. aureus / CoNS | Post-neurosurgical, VP shunt infections, Ommaya reservoir |
| Mycobacterium tuberculosis | TB contact/endemic areas, HIV, immunocompromised |
| Meningococcal serogroups | A, B, C, W-135, Y — serogroup B still most common in many Western countries |
Non-Bacterial Causes
- Viral: Enteroviruses (most common overall), HSV-2 (recurrent meningitis), VZV, EBV, CMV, HIV (acute seroconversion), West Nile virus, mumps
- Fungal: Cryptococcus neoformans/gattii (HIV/AIDS, organ transplant, haematological malignancy); Candida, Aspergillus (nosocomial/immunocompromised)
- Parasitic: Angiostrongylus cantonensis (eosinophilic meningitis), Gnathostoma spinigerum (SE Asia)
- Non-infectious: Sarcoidosis, systemic lupus erythematosus (SLE), Behçet disease, neoplastic/carcinomatous meningitis, drug-induced (NSAIDs, TMP-SMX, IVIG)
4. PATHOPHYSIOLOGY
The pathophysiology is best understood in bacterial meningitis and applies across many forms. (Harrison's 22E, Chapter 143)
Step 1 — Colonisation and Invasion
The most common causative bacteria (S. pneumoniae, N. meningitidis) initially colonise the nasopharynx by attaching to epithelial cells. They are transported across epithelial cells in membrane-bound vacuoles or invade by creating separations in apical tight junctions of columnar epithelial cells.
Step 2 — Bacteraemia
Once in the bloodstream, bacteria evade phagocytosis by neutrophils and complement-mediated bactericidal activity via their polysaccharide capsule. Bloodborne bacteria can reach the intraventricular choroid plexus, directly infect choroid plexus epithelial cells, and gain access to the CSF. Some bacteria (e.g., S. pneumoniae) adhere to cerebral capillary endothelial cells and migrate through or between them to reach the CSF.
Step 3 — Replication in CSF
Bacteria multiply rapidly within CSF because:
- Normal CSF contains few WBCs
- Relatively small amounts of complement proteins and immunoglobulins — insufficient for effective opsonisation
- Fluid nature of CSF is less conducive to phagocytosis than solid tissue
Step 4 — Inflammatory Cascade (Critical Step)
"Many of the neurologic manifestations and complications of bacterial meningitis result from the immune response to the invading pathogen rather than from direct bacteria-induced tissue injury." — Harrison's 22E
- Lysis of bacteria → release of cell-wall components (LPS from Gram-negatives; teichoic acid and peptidoglycans from S. pneumoniae) into the SAS
- These stimulate microglia, astrocytes, monocytes, endothelial cells, and CSF leukocytes to produce TNF-α and IL-1β within 1–2 hours
- This is followed by: ↑ CSF protein concentration + leukocytosis
- Chemokines and proinflammatory cytokines → leukocyte migration into CSF
- Bacteraemia and cytokines → excitatory amino acids, reactive oxygen species (ROS), nitric oxide, peroxynitrite → neuronal death (especially hippocampal dentate gyrus)
Step 5 — Blood-Brain Barrier Disruption and Oedema
- TNF-α + IL-1β act synergistically to increase BBB permeability → vasogenic oedema + leakage of serum proteins into SAS
- Subarachnoid exudate obstructs CSF flow through the ventricular system and impairs arachnoid granulation resorption → obstructive and communicating hydrocephalus + interstitial oedema
- Inflammatory cytokines upregulate selectins on cerebral endothelium → leukocyte adherence → further BBB disruption
- Neutrophil degranulation → toxic metabolites → cytotoxic oedema, cell injury and death
Step 6 — Vascular Injury and Raised ICP
- Early: ↑ cerebral blood flow; later: ↓ CBF with loss of cerebrovascular autoregulation
- Vasculitis (endothelial swelling, intimal thickening) → narrowing of arteries at the base of the brain, ischaemia and infarction
- Thrombosis of middle cerebral artery branches, major cerebral venous sinuses, and cortical veins
- The combination of interstitial + vasogenic + cytotoxic oedema → raised ICP → coma
- Cerebral herniation results from focal or generalised cerebral oedema; hydrocephalus and dural sinus/cortical vein thrombosis contribute
Vascular Histopathology (Adams and Victor's)
- Within 48–72 hours: endothelial cells swell and multiply, adventitia infiltrated by neutrophils
- Focal necrosis of arterial wall, subintimal fibrosis
- Veins more susceptible to thrombosis due to thinner walls and slower flow
- Cortical thrombophlebitis does not usually develop before the end of the second week
- In TB and syphilitic meningitis: Heubner arteritis is a prominent vascular feature
5. CLINICAL FEATURES
Classic Presentation
Meningitis can present as an acute fulminant illness (progressing in hours) or as a subacute infection (progressing over 1–7 days). (Harrison's 22E)
The classic triad of bacterial meningitis:
- Fever
- Headache (severe, generalised)
- Neck stiffness (nuchal rigidity)
This triad is present in only 44% of patients but 95% present with at least 2 of: headache, fever, neck stiffness, or altered consciousness.
Other Key Symptoms and Signs
| Feature | Notes |
|---|
| Photophobia | Very common |
| Phonophobia | Common |
| Nausea and vomiting | Common |
| Altered consciousness | ~75–80% of patients (lethargy to coma) |
| Seizures | Occur in 15–30% of patients early in course |
| Focal neurological deficits | In ~33% (cranial nerve palsies, hemiparesis, dysphasia) |
Meningeal Signs
| Sign | Description | Mechanism |
|---|
| Nuchal rigidity | Resistance to passive neck flexion | Meningeal irritation — "nocifensive flexor reflex" (Adams and Victor's) |
| Kernig's sign | With hip flexed at 90°, inability to fully extend the knee due to pain/spasm | Stretches inflamed meninges over lumbar nerve roots |
| Brudzinski's sign | Passive neck flexion causes involuntary hip and knee flexion | Same meningeal irritation mechanism |
Note: In infants <3 months old, meningeal signs (Kernig's, Brudzinski's) occur in <10% of cases and increase with age. In elderly and immunocompromised patients, meningism may be absent.
Rash in Meningococcal Disease
- Petechial or purpuric skin lesions are a critical diagnostic clue for meningococcal disease
- The rash results from dermal seeding of organisms with vascular endothelial damage
- In some patients the disease is fulminant, progressing to death within hours of symptom onset
- Skin biopsy of petechial lesions may reveal organisms on Gram stain — Harrison's 22E
- Rash begins as non-specific erythematous maculopapular → petechial → purpuric (non-blanching)
Raised ICP Signs
- Papilloedema (may be absent in acute setting)
- Cushing's triad (hypertension, bradycardia, irregular breathing) — late sign
- Pupillary changes, posturing (decorticate/decerebrate)
- Sixth nerve palsy (false localising sign)
Viral Meningitis (Aseptic Meningitis)
- Headache (almost invariably present, often frontal or retroorbital)
- Photophobia, pain on moving the eyes
- Nuchal rigidity (usually mild, present only near the limit of anteflexion)
- Malaise, myalgia, anorexia, nausea, vomiting, diarrhoea
- Mild lethargy or drowsiness
- No profound alteration in consciousness (distinguishes from encephalitis)
- No focal neurological signs or seizures (if present, suspect encephalitis)
- Harrison's 22E, Chapter 143
TB Meningitis — Subacute/Chronic Features (PUO Relevance)
- Insidious onset over weeks with low-grade fever, malaise, anorexia, weight loss
- Headache and meningism develop gradually
- Cranial nerve palsies (especially CN III, IV, VI, VII) — from basilar meningitis
- Altered consciousness and focal deficits develop later
- Choroidal tubercles on fundoscopy (pathognomonic when present)
- Hyponatraemia (SIADH) is common
Cryptococcal Meningitis (PUO Relevance)
- Insidious onset over weeks; often in HIV/AIDS (CD4 <100) or organ transplant recipients
- Fever, headache, altered mental status
- Meningism may be minimal or absent
- Elevated ICP is a key feature (>25 cmH₂O) — can cause papilloedema and visual loss
6. INVESTIGATIONS
A. Imaging Before Lumbar Puncture
CT Head is indicated before LP if ANY of:
- Immunocompromised state
- History of CNS disease (mass lesion, stroke, focal infection)
- New-onset seizures
- Papilloedema
- Altered level of consciousness
- Focal neurological deficit
Do not delay antibiotics for CT or LP — in suspected bacterial meningitis, blood cultures should be drawn and empirical antibiotics started immediately if CT or LP cannot be performed without delay.
CT findings in meningitis: May be normal or show diffuse cerebral oedema, hydrocephalus, or complications (subdural empyema, cerebral infarction, abscess). Meningeal enhancement is seen on gadolinium-enhanced MRI.
MRI: More sensitive than CT. Can show basal meningeal enhancement (especially in TB meningitis), complications including cerebral infarction, hydrocephalus.
B. Lumbar Puncture and CSF Analysis
The most important diagnostic test. CSF should be sent for:
- Opening pressure
- Appearance (clear/turbid/xanthochromic)
- Cell count with differential
- Protein
- Glucose (simultaneous serum glucose)
- Gram stain
- Culture and sensitivity
- PCR (bacterial multiplex, viral PCR, TB PCR/GeneXpert)
- India ink (for Cryptococcus)
- Cryptococcal antigen (CrAg) — sensitivity >90%
- AFB smear and culture (if TB suspected)
- Adenosine deaminase (ADA) — elevated in TB meningitis
CSF Interpretation Table
| Parameter | Bacterial | Viral (Aseptic) | TB | Fungal (Crypto) |
|---|
| Appearance | Turbid/purulent | Clear | Clear/slightly turbid | Clear/slightly turbid |
| Opening pressure | >180 mmH₂O | 100–350 mmH₂O | Elevated | Markedly elevated |
| WBC (cells/μL) | 10–10,000 (PMN) | 25–500 (lymphocytes) | 100–500 (lymphocytes) | 20–500 (lymphocytes) |
| Protein (g/L) | >0.45 (often >1) | Normal to slightly ↑ | Elevated (1–5) | Elevated |
| Glucose (mmol/L) | <2.2 | Normal | Low | Low |
| CSF:serum glucose | <0.4 | >0.6 | <0.5 | <0.5 |
| Gram stain | Positive >60% | Negative | Negative | Negative (India ink positive) |
| Culture | Positive >80% | Negative | Positive (4–8 wks) | Positive in 4 wks |
| Special tests | — | PCR (enterovirus, HSV) | ADA ↑, TB PCR, AFB culture | CrAg >90% sensitive |
Sources: Harrison's 22E; Goldman-Cecil Medicine
C. Blood Investigations
- Blood cultures (2 sets before antibiotics if LP can be delayed; do not delay antibiotics)
- FBC — leucocytosis (bacterial); lymphocytosis (viral/TB/fungal)
- CRP and ESR — markedly elevated in bacterial
- Procalcitonin — elevated in bacterial meningitis; helps distinguish bacterial from viral
- Electrolytes — hyponatraemia (SIADH, especially TB meningitis)
- Serum glucose (simultaneous with CSF)
- Coagulation profile — DIC may complicate bacterial meningitis
- HIV test — if cryptococcal/TB meningitis suspected
- Blood glucose for CSF:serum ratio
D. Microbiology
- Gram stain: Positive in >60% of bacterial meningitis cases — Harrison's 22E
- Culture: Positive in >80%
- PCR multiplex panel (FilmArray Meningitis/Encephalitis Panel): HSV-1, HSV-2, enteroviruses, VZV, HHV-6, human parechovirus, bacterial targets — Harrison's 22E
- India ink: Identifies Cryptococcus (large capsule)
- Cryptococcal antigen (CrAg): Sensitivity >90%, specificity >90%
- AFB smear + culture + GeneXpert MTB/RIF: TB meningitis
- Petechial skin biopsy: Gram stain may reveal N. meningitidis
7. MANAGEMENT
PRINCIPLE: Bacterial Meningitis is a Medical Emergency
"The goal is to begin antibiotic therapy within 60 minutes of a patient's arrival in the emergency room." — Harrison's 22E
Step 1 — Empirical Therapy (Before Culture Results)
Empirical regimen must be started immediately. Standard approach for community-acquired bacterial meningitis in adults:
| Drug | Role |
|---|
| Dexamethasone 0.15 mg/kg IV q6h × 4 days | Anti-inflammatory; given before or with the first antibiotic dose |
| Ceftriaxone 2 g IV q12h (or Cefotaxime 2 g IV q6h) | Covers S. pneumoniae, N. meningitidis, H. influenzae, Group B Streptococcus |
| Vancomycin 15–20 mg/kg IV q8–12h | Covers penicillin/cephalosporin-resistant S. pneumoniae |
| Ampicillin 2 g IV q4h | Add if age <3 months, >55 years, or immunocompromised (for Listeria) |
| Acyclovir 10 mg/kg IV q8h | Add as HSV encephalitis is the leading differential |
| Metronidazole | Add if otitis, sinusitis, or mastoiditis (cover anaerobes) |
Note on dexamethasone: Most beneficial in pneumococcal meningitis; reduces hearing loss and mortality. Should be given 30 minutes before or simultaneously with the first antibiotic dose. Harrison's 22E
Hospital-acquired/post-neurosurgical meningitis: Vancomycin + cefepime or meropenem (to cover Pseudomonas and MRSA).
Step 2 — Specific (Targeted) Therapy by Organism
| Organism | Preferred Antibiotic | Alternative |
|---|
| N. meningitidis (penicillin-sensitive) | Penicillin G | Ceftriaxone |
| N. meningitidis (penicillin-resistant) | Ceftriaxone | Meropenem |
| S. pneumoniae (penicillin-sensitive) | Penicillin G | Ceftriaxone |
| S. pneumoniae (cephalosporin-resistant) | Vancomycin + ceftriaxone | Vancomycin + rifampicin |
| L. monocytogenes | Ampicillin (+ gentamicin) | TMP-SMX |
| H. influenzae (β-lactamase negative) | Ampicillin | Ceftriaxone |
| H. influenzae (β-lactamase positive) | Ceftriaxone | — |
| Gram-negative bacilli (incl. Pseudomonas) | Cefepime or meropenem | Ciprofloxacin |
| S. aureus (MSSA) | Nafcillin/oxacillin | — |
| S. aureus (MRSA) | Vancomycin | Linezolid |
Source: Harrison's 22E, Table 143-3
Duration of Antibiotic Therapy
| Organism | Duration |
|---|
| N. meningitidis | 7 days |
| H. influenzae | 7 days |
| S. pneumoniae | 10–14 days |
| L. monocytogenes | 21 days (minimum) |
| Gram-negative bacilli | 21 days |
| Group B Streptococcus | 14–21 days |
Step 3 — TB Meningitis Management
Standard RHEZ regimen (as per Malaysian National TB Programme guidelines and Harrison's):
- Isoniazid (H) 5 mg/kg/day + Rifampicin (R) 10 mg/kg/day + Pyrazinamide (Z) 25 mg/kg/day + Ethambutol (E) 15 mg/kg/day for 2 months, then
- Isoniazid + Rifampicin for 7–10 months (total duration: 9–12 months)
- Corticosteroids (Dexamethasone): Reduces mortality and morbidity in TB meningitis (WHO-recommended)
- Pyridoxine (Vitamin B6) 10 mg/day to prevent INH-related neuropathy
Step 4 — Cryptococcal Meningitis Management (3-Phase Approach)
(Harrison's 22E; Bradley and Daroff)
| Phase | Regimen | Duration |
|---|
| Induction | Amphotericin B deoxycholate 0.7–1 mg/kg/day IV + Flucytosine 100 mg/kg/day in 4 divided doses | 2 weeks minimum |
| Consolidation | Fluconazole 400 mg/day oral | 8 weeks |
| Maintenance | Fluconazole 200 mg/day oral | Lifelong (if HIV) or until immune reconstitution |
- ICP management is critical in cryptococcal meningitis — serial therapeutic LPs (remove 20–30 mL CSF) or lumbar drain/ventriculostomy if refractory
- Lipid formulations of AmB (L-AmB) preferred in resource-rich settings to reduce nephrotoxicity
Step 5 — Viral Meningitis Management
- Largely supportive — analgesia, antipyretics, antiemetics, IV fluids
- Acyclovir 10 mg/kg IV q8h for HSV meningitis/encephalitis (empirically given if HSV suspected)
- Enteroviruses: no specific antiviral; Pleconaril (investigational)
- Recovery usually within 7–14 days
Step 6 — Supportive Care and ICP Management
- Elevation of head to 30–45°
- Intubation and hyperventilation (PaCO₂ 25–30 mmHg) — temporary ICP reduction
- Mannitol 0.25–0.5 g/kg IV — osmotic diuresis
- ICP monitoring device in patients with raised ICP — Harrison's 22E
- Seizure management: Benzodiazepines acutely; phenytoin/levetiracetam for prophylaxis
- Fluid management: Avoid hypovolaemia; treat SIADH with fluid restriction
- ICU care for patients with altered consciousness, need for ventilation, or haemodynamic instability
Step 7 — Chemoprophylaxis (Close Contacts of Meningococcal Disease)
| Drug | Dose | Duration |
|---|
| Rifampicin | 600 mg PO BD (adults) | 2 days |
| Ciprofloxacin | 500 mg PO single dose | Single dose |
| Ceftriaxone | 250 mg IM single dose (adults); 125 mg IM (<15 years) | Single dose |
| Azithromycin | 500 mg PO single dose | Single dose (alternative) |
Step 8 — Vaccination (Prevention)
| Vaccine | Target | Notes |
|---|
| Meningococcal quadrivalent conjugate (MenACWY) | Serogroups A, C, W-135, Y | Recommended 11–18 years; complement-deficient patients |
| Meningococcal serogroup B (MenB) | Serogroup B | Adolescents 16–23 years; does not reduce nasopharyngeal carriage |
| Pentavalent meningococcal vaccine (A, B, C, W, Y) | Serogroups A–Y | Recently available |
| Pneumococcal conjugate (PCV13/PCV15) | S. pneumoniae | All infants; adults >65; immunocompromised |
| Pneumococcal polysaccharide (PPSV23) | S. pneumoniae | Adults >65; high-risk adults |
| Hib conjugate | H. influenzae type b | Routine infant immunisation; responsible for dramatic decline in Hib meningitis |
8. COMPLICATIONS
| Complication | Mechanism |
|---|
| Cerebral herniation | Cerebral oedema (vasogenic, cytotoxic, interstitial) + hydrocephalus → uncal or tonsillar herniation |
| Hydrocephalus | Obstructed CSF flow by purulent exudate (acute); meningeal fibrosis (chronic) |
| Cerebral infarction | Vasculitis, arterial thrombosis (MCA branches), venous sinus thrombosis, cortical thrombophlebitis |
| Subdural empyema | Extension of infection into subdural space |
| SIADH / Hyponatraemia | Especially in TB meningitis; fluid restriction required |
| DIC / Septic shock | Meningococcaemia; fulminant course |
| Cranial nerve palsies | Basal meningitis (CN III, IV, VI, VII, VIII); especially in TB and fungal |
| Seizures | Cortical irritation, cerebral infarction, hyponatraemia |
| Subdural effusion | Especially in children; impaired alertness, fever persistence |
| Spinal cord involvement | Radiculomyelitis; spinal cord infarction |
Cerebral herniation subtypes (Adams and Victor's 12E):
- Transtentorial (uncal) herniation: Third nerve compression → unilateral dilated pupil
- Central herniation: Bilateral cortical dysfunction
- Cerebellar/tonsillar herniation: Cervical cord compression → quadriplegia, cardiorespiratory arrest
9. PROGNOSIS AND OUTCOMES
| Organism | Mortality |
|---|
| H. influenzae | 3–7% |
| N. meningitidis | 3–7% |
| Group B Streptococcus | 3–7% |
| L. monocytogenes | ~15% |
| S. pneumoniae | ~20% |
| Cryptococcal (developed world) | 10–25% |
| Cryptococcal (resource-poor settings) | ~43% |
Sources: Harrison's 22E; Bradley and Daroff's
Neurological Sequelae (moderate/severe in ~25% of survivors): (Harrison's 22E)
- Decreased intellectual function and memory impairment
- Sensorineural hearing loss and dizziness (most common sequela — highest with pneumococcal meningitis)
- Seizures
- Gait disturbances
- Hydrocephalus (communicating or obstructive)
- Visual impairment / optic atrophy
Poor Prognostic Factors (Harrison's 22E):
- Decreased level of consciousness on admission
- Onset of seizures within 24 hours of admission
- Signs of raised ICP
- Young age (infancy) and age >50
- Comorbidities including shock and/or need for mechanical ventilation
- Delay in initiation of treatment
- CSF glucose <2.2 mmol/L (<40 mg/dL)
- CSF protein >3 g/L (>300 mg/dL)
SUMMARY TABLE: Key Differentiating Features
| Feature | Bacterial | Viral | TB | Cryptococcal |
|---|
| Onset | Acute (hours–days) | Acute | Subacute (weeks) | Subacute (weeks) |
| Fever | High | Moderate | Low-grade | Low-grade |
| CSF WBC | High PMN | Low lymphocytes | Moderate lymphocytes | Low lymphocytes |
| CSF glucose | Low | Normal | Low | Low |
| CSF protein | High | Slightly elevated | High | Elevated |
| Gram stain | Often positive | Negative | Negative | India ink positive |
| Key test | Culture, PCR | PCR | TB PCR, ADA, culture | CrAg, India ink |
| Treatment | Antibiotics + steroids | Supportive ± acyclovir | RHEZ + steroids | AmB + 5FC → fluconazole |
| Prognosis | Mortality 5–20% | Excellent | High morbidity/mortality | High mortality in HIV |
KEY REFERENCES
- Harrison's Principles of Internal Medicine 22E (2025, McGraw-Hill) — Chapter 143: Meningitis, Encephalitis, Brain Abscess, and Empyema; Chapter 22: Fever of Unknown Origin
- Goldman-Cecil Medicine International Edition — Chapter 381: Meningitis
- Adams and Victor's Principles of Neurology, 12th Edition — Chapter 31: Bacterial and Fungal Infections of the Nervous System
- Bradley and Daroff's Neurology in Clinical Practice — Cryptococcal Meningitis and HIV-related Neurological Infections
- Malaysian National TB Programme (NTP) Guidelines — TB Meningitis Management
---The above is your comprehensive seminar reference on meningitis in the context of PUO. Here is a quick overview of what is covered:
What's Included
PUO Link: Subacute/chronic meningitis (TB, cryptococcal, partially-treated bacterial) is a recognised PUO cause — any PUO patient with headache or neck stiffness warrants CSF examination.
Definition: Bacterial meningitis = acute purulent infection of the subarachnoid space with CNS inflammation (Harrison's 22E). Goldman-Cecil extends this to include all aetiologies with their respective CSF patterns.
Epidemiology: ~1.4/100,000 in developed countries; dramatically reduced by vaccines. TB and fungal meningitis carry special relevance in Malaysia. Angiostrongylus cantonensis and B. pseudomallei (melioidosis) are notable SE Asian organisms.
Aetiology: Full breakdown by organism, age group, and risk factor — bacterial, viral, TB, fungal, parasitic, and non-infectious causes.
Pathophysiology: Step-by-step from nasopharyngeal colonisation → bacteraemia → CSF invasion → inflammatory cascade (TNF-α/IL-1β) → BBB disruption → vasogenic/cytotoxic/interstitial oedema → raised ICP → herniation.
Clinical Features: Classic triad (present in only 44%); meningeal signs (Kernig's, Brudzinski's); non-blanching rash in meningococcaemia; subacute features of TB/cryptococcal meningitis.
Investigations: Full CSF interpretation table comparing all 4 types; blood workup; imaging indications; microbiology (Gram stain, CrAg, TB PCR, ADA, multiplex PCR panels).
Management: Empirical antibiotics within 60 minutes + dexamethasone; organism-specific therapy tables; TB RHEZ regimen; cryptococcal 3-phase protocol (AmB + flucytosine → fluconazole); chemoprophylaxis; vaccines.
Prognosis: Mortality 3–20% depending on organism; ~25% of survivors have moderate/severe sequelae; key poor prognostic factors listed.